Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cardium Therapeutics and its subsidiary, Tissue Repair Company, have signed a contract with AMRI for its Burlington site to manufacture sterile pre-filled syringes in support of the US introduction of Excellagen.
Subscribe to our email newsletter
Excellagen is a formulated collagen-based product indicated for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds.
Cardium chairman and CEO Christopher Reinhard said, "We look forward to an ongoing and collaborative relationship with AMRI as we continue to introduce Excellagen to the U.S. market."
The collagen-based topical gel (2.6%) is designed to support favorable wound-care management and is applied through easy-to-control, pre-filled, single use syringes.
AMRI chairman, president and CEO Thomas E. D’Ambra said the company will address the technical challenges and ensure the highest manufacturing standards.
"Supporting the Excellagen commercial market entry is a good illustration of further opportunities ahead and a validation of the market potential for AMRI’s participation in the aseptic dosage form business." D’Ambra added.